Acurx Pharmaceuticals Announces Presentation of Ibezapolosta

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Related Keywords

United States , Spain , Switzerland , Barcelona , Comunidad Autonoma De Cataluna , America , Kevin Garey , Eugenie Basseres , Davidp Luci , Society Or Healthcare Epidemiology Of America , Exchange Commission , Research Scientist , Company Scientific Advisory Board , Prnewswire Acurx Pharmaceuticals Inc , Company Ph , Global European Society Of Clinical Microbiology , Trial Oversight Committee , Drug Administration , Acurx Pharmaceuticals , University Of Houston College Pharmacy , Nasdaq , Data Monitoring Committee , Acurx Pharmaceuticals Inc , Exchange Commission On Form , Infectious Diseases Society Of America , European Society Of Clinical Microbiology , European Society , Clinical Microbiology , Infectious Diseases , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Double Blind Study , Ibezapolstat Compared , Executive Committee , Ibezapolstat Phase , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Private Securities Litigation Reform Act ,